Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03860831
Other study ID # R 57/2018
Secondary ID
Status Recruiting
Phase Phase 1
First received
Last updated
Start date March 6, 2019
Est. completion date July 2019

Study information

Verified date March 2019
Source Ain Shams University
Contact dean of faculty of medicine, MD
Phone 0020224821894
Email dean@med.asu.edu.eg
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Ketamine and Midazolam are well known sedative drugs that can be given through different routes such as intravenous, intramuscular, oral, rectal and intranasal route. Anesthetic staff usually prefer intravenous route but sometimes inserting venous access is difficult in uncooperative mentally disabled children. Intranasal ketamine+Midazolam can be a needless effective alternative in these vulnerable patients


Description:

Sedation and analgesia decreases the need for general anesthesia outside the operating room. Intravenous route is the standard way of sedation, but its use can be limited in uncooperative mentally disabled children. Active Physical restraint of children causes emotional trauma for both parents and children particularly in these patients. Oral sedation has multiple disadvantages as delayed onset of action, better taste, the need of different types of syrup or honey according to the preference of the patient, children may refuse to take oral drugs or even spit it and it also causes postoperative nausea and vomiting. In contrast, intramuscular sedation is an easy effective way of administration and it is preferred due to its rapid onset of action and higher predictability of the duration, however, fear of the pain of injections is considered a disadvantage in this vulnerable pediatric patients. nasal route is an important alternative route because it is a painless and needless approach with rapid drug absorption from nasal mucosa reaching the cerebrospinal fluid and bypassing the first pass metabolism in the liver. Intranasal midazolam for sedation of children was first described by Wilton et al .Recently studies proved the use of nasal ketamine spray for treatment of resistant depression in adults. Ketamine as a premedication in children has been also successfully given through the nasal route. In Ain shams University hospitals we give either oral Midazolam or intramuscular Ketamine followed by sevoflurane or propofol for pediatric procedural sedation. Nasal Midazolam or Ketamine has not been tried despite being a feasible choice with many possible advantages. Combination of ketamine and midazolam causes deeper sedation and less dysphoric reaction of ketamine so in this study, we evaluate the efficacy and safety of administration of this combination through intranasal route for procedural sedation in children with mental developmental delay outside the operating room.

After approval from our Ethical Committee, written informed consent from the parents will be taken. Forty children presented with autism,mongolism or cerebral palsy classified as American Society of Anesthesiologists (ASA) physical status I and II, aged between 4 and 12 years will be enrolled in our study, and computer-generated assignment will be used for randomization and to allocate patients to one of two equal study groups.

patients will fulfill the fasting hours if elective while the patients in ER will be asked to wait for six hours after last meal.

Patients will be divided into two groups Group IN:will receive intranasal ketamine 5 mg/kg and midazolam 0.2 mg/kg, and we will give intranasal sedatives by using mucosal atomisation device.

Group IM:will receive intramuscular ketamine 5 mg/kg, and midazolam 0.2 mg/kg Sedation levels after 10, 20, and 30 min will be evaluated by Pediatric Sedation State Scale (PSSS).

Drugs will be given 15- 20 minutes before procedure then Heart rate (HR), Oxygen saturation (Spo2), and mean arterial blood pressure (MBP) will be continuously monitored and recorded every 5 min after drug administration for 60 minutes .

Local anesthesia will be given in painful procedures. Intravenous ketamine 1 mg/kg will be given if needed due to prolongation of procedure or if required sedation level not reached through intranasal or intramuscular route.

respiratory events as airway obstruction and desaturation less than 92% will be treated by jaw thrust and oxygen supplementation, apnea or laryngeal spasm will be managed with endotracheal intubation. Wheezing will be recorded and properly managed with bronchodilators and steroids.

Emergency cart and drugs will be available for haemodynamic and respiratory instabilities.

After recovery of the patients, parents and doctors will rate their overall satisfaction by using simple image of 5 point Likert scale.

Primary outcome: effectiveness of sedation. Secondary outcome: onset, duration of sedation, adverse effect, parents and doctor satisfaction.

End point of the study: if our technique failed to sedate the patients general anesthesia will be given either intravenous ketamine 1mg/kg or inhalational sevoflurane to complete the procedure.


Recruitment information / eligibility

Status Recruiting
Enrollment 40
Est. completion date July 2019
Est. primary completion date June 2019
Accepts healthy volunteers No
Gender All
Age group 4 Years to 12 Years
Eligibility Inclusion Criteria:

- Inclusion criteria of the patients were:

- Mentally affected children (autism,down syndrome and cerebral palsy)

- children who are scheduled for Short procedures (30 minutes or less) under sedation

Exclusion Criteria:

- parents refusal.

- child cooperation and acceptance of venipuncture or cannula in situ.

- children with known allergy to ketamine or midazolam.

- liver or renal organ dysfunction.

- suspected difficult cannulation.

- congenital heart disease.

- active pulmonary infection or asthma.

- increased intracranial tension or intraocular pressure.

- severe trauma0

- significant nasal discharge or obstruction.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Ketamine + midazolam
Group IN received intranasal midazolam (0.2 mg/kg) +ketamine (5mg/kg). Group IM received intramuscular midazolam (0.2 mg/kg) +ketamine (5mg/kg) in the gluteal region.

Locations

Country Name City State
Egypt Ainshams hospitals Cairo
Egypt Sanaa Farag Mahmoud Cairo New Cairo

Sponsors (1)

Lead Sponsor Collaborator
Ain Shams University

Country where clinical trial is conducted

Egypt, 

References & Publications (5)

Cravero JP, Askins N, Sriswasdi P, Tsze DS, Zurakowski D, Sinnott S. Validation of the Pediatric Sedation State Scale. Pediatrics. 2017 May;139(5). pii: e20162897. doi: 10.1542/peds.2016-2897. — View Citation

Dallimore D, Herd DW, Short T, Anderson BJ. Dosing ketamine for pediatric procedural sedation in the emergency department. Pediatr Emerg Care. 2008 Aug;24(8):529-33. doi: 10.1097/PEC.0b013e318180fdb5. — View Citation

Lee-Kim SJ, Fadavi S, Punwani I, Koerber A. Nasal versus oral midazolam sedation for pediatric dental patients. J Dent Child (Chic). 2004 May-Aug;71(2):126-30. — View Citation

Malamed SF. Sedation: A Guide to Patient Management. New York, NY: CV: Mosby-Year Book Inc; 1995. 3rd ed.

Ochs-Ross R,et al. Efficacy and safety of intranasal esketamine plus an oral antidepressant in eldely patients with treatment-resistant depression.Poster PS066 presented at CINP 2018,16-19 june, Vienna, Austria.

Outcome

Type Measure Description Time frame Safety issue
Primary change in sedation level after intranasal or intramuscular ketamine midazolam mixture administration. sedation level measured by Pediatric Sedation State Scale (PSSS): State 5: Movement impedes procedure and requires forceful immobilization
State 4: Movement requires gentle immobilization for positioning
State 3: Facial expression of pain or anxiety
State 2: Quiet, not moving, no frown, no verbalization of complaint (ideal state)
State 1: Deeply asleep with normal vital signs, but requires airway intervention or assistance (e.g., central or obstructive apnea)
State 0: Deeply asleep with abnormal physiologic parameters that require acute intervention (e.g., O2 saturation <90%, hypotension, bradycardia)
highest score is 0 and least score is 5
every 10 minutes through the study till one hour after administration
Secondary parents satisfaction image form of 5 point likert scale. 5-very satisfied 4-Satisfied 3-Neither satisfied nor dissatisfied 2-Dissatisfied
1-Very dissatisfied least score is 1 and highest score is 5
two hours after administration
See also
  Status Clinical Trial Phase
Recruiting NCT03692390 - Virtual Reality vs. Standard-of-Care for Comfort Before and After Sedation in the Emergency Department N/A
Completed NCT02145169 - Inhaled Nitrous Oxide for the Prevention of Emergence Reaction During Ketamine Administration in Adults, a Pilot Study N/A
Recruiting NCT05595798 - EEG Spectral Pattern of Deep Sedation-induced Airway Adverse Effects
Completed NCT01260662 - Randomized Clinical Trial of Propofol, 1:1 and 4:1 Combination of Propofol and Ketamine for Procedural Sedation Phase 4
Completed NCT00784498 - Procedural Sedation Using Propofol Versus Midazolam/Ketamine in the Adult Emergency Department Phase 4
Completed NCT00327392 - A Safety Study of AQUAVAN® (Fospropofol Disodium) Injection for Sedation During Minor Surgical Procedures. Phase 2/Phase 3
Recruiting NCT04873596 - Dexmedetomidine and Midazolam Nebulization as Sedation During Cesarean Delivery in Pre-eclampsia Phase 2
Completed NCT03329014 - A Trial of Intranasal Remimazolam Pharmacokinetics, Pharmacodynamics, Safety and Bioavailability Phase 1
Recruiting NCT06414395 - The Effects of Different Loading Doses of Dexmedetomidine on The Bispectral Index-Guided Propofol Sedation in Patients Undergoing Advanced Upper Gastrointestinal Endoscopic Procedures: A Randomized Control Study Phase 4
Completed NCT00869440 - Dose-Finding Safety Study Evaluating Remimazolam (CNS 7056) in Patients Undergoing Diagnostic Upper GI Endoscopy Phase 2
Not yet recruiting NCT05757622 - Electroencephalogram Based Real-Time Sedation Level Prediction
Completed NCT03799783 - The Use of Dexmedetomidine for EEG Sedation in Children With Behavioural Disorders Phase 2
Completed NCT02180737 - Dexmedetomidine for Sedation During Radiological Interventional Procedures Phase 4
Not yet recruiting NCT01227174 - Safety and Efficacy of Propofol Only Sedation in Oral and Maxillofacial Surgery Phase 4
Recruiting NCT03499886 - Low-Dose Intravenous Ketamine Bolus Versus Conventional Technique Phase 2/Phase 3
Completed NCT03747432 - Comparison of Procedural Sedation With Propofol and Dexmedetomidine During Transcatheter Aortic Valve Implantation Phase 4
Recruiting NCT06203522 - Factors Associated With Successful Completion of MRI in Children Undergoing a Vigil Sedation With Dexmedetomidin
Withdrawn NCT05783492 - INK Feasibility Study Phase 3
Recruiting NCT04686448 - Ketofol Versus Fenofol as Procedural Sedation for Carpal Tunnel Release Phase 1/Phase 2
Completed NCT02955732 - Pharmacological Characteristics of Intranasally Given Dexmedetomidine in Paediatric Patients Phase 4